June 24, 2021: Effect of efavirenz metabolism on weight change; determinants of weight gain when switching meds; metabolic effects of DTG vs. TAF; food security vs. nutrition security.
Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
March 19, 2020: Mood disorders and metabolic syndrome; comorbidity burden among women living with HIV; two-year weight gain after switching to integrase; long-term adipose tissue density trends.
Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
Years after their body weight stabilized, HIV-positive men with a wasting history had significantly lower grip strength than HIV-positive men who never had wasting, according to a Multicenter AIDS Cohort Study (MACS) analysis.
"Various fat accumulation syndromes remain a bedeviling problem for our patients," writes Paul Sax, M.D. A newly approved fat-removal drug has him wondering about its potential value for people with HIV.
Having a high viral load when starting treatment was most consistently associated with body composition changes after starting antiretroviral therapy.
Researchers found that people with higher viral loads when they first start ART are more likely to have substantial body composition changes than those who start treatment with a lower viral load.